10-Q: CEL-SCI Reports Q1 2025 Results, Focuses on Multikine Confirmatory Study

CEL-SCI Corporation reports its financial results for the quarter ended December 31, 2024, and provides an update on its clinical development program for Multikine.

Summary

• CEL-SCI Corporation reported a net loss of $7.07 million for the three months ended December 31, 2024, compared to a net loss of $6.71 million for the same period in 2023.
• Research and development expenses remained relatively constant at approximately $4.4 million for both periods.
• General and administrative expenses increased by approximately $0.3 million, or 15%, compared to the prior year.
• The company's cash and cash equivalents decreased slightly to $4.61 million from $4.74 million at the beginning of the quarter.
• CEL-SCI is focused on advancing its investigational immunotherapy, Multikine, and plans to initiate a confirmatory registration study in Q1/Q2 2025, with full enrollment expected in Q2 2026.
• The company believes Multikine has shown significant survival benefit in a target population of head and neck cancer patients.
• CEL-SCI acknowledges substantial doubt about its ability to continue as a going concern due to recurring losses and future liquidity needs.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the progress with the FDA and the promising survival data for Multikine, but is tempered by the company's financial losses and going concern uncertainty.

Positives

• The FDA has indicated that CEL-SCI may proceed with a confirmatory registration study for Multikine.
• Multikine has demonstrated a significant survival benefit in a specific target population in the Phase III study, with a 73% survival rate compared to 45% in the control group.
• The company successfully completed a public offering in December 2024, raising approximately $4.4 million.
• CEL-SCI aims to begin the 212-patient confirmatory registration study in Q1/Q2 2025, with full enrollment expected in Q2 2026 with the potential to seek early approval after full enrollment.

Negatives

• CEL-SCI reported a net loss of $7.07 million for the quarter ended December 31, 2024.
• The company acknowledges substantial doubt about its ability to continue as a going concern due to recurring losses and future liquidity needs.
• The company's disclosure controls and procedures were not effective as of December 31, 2024 due to the material weaknesses described in the Company's Annual Report on Form 10-K for the year ended September 30, 2024.

Risks

• The company's ability to raise additional capital is dependent on market conditions, which are outside of its control.
• There is no assurance that the company will be successful in raising additional funds on a timely basis or that the funds will be available on acceptable terms or at all.
• The company's ability to obtain regulatory approval for Multikine is uncertain.
• If the company does not raise the necessary amounts of money, it may have to curtail its operations until such time as it is able to raise the required funding.

Future Outlook

CEL-SCI plans to initiate a confirmatory registration study of Multikine in Q1/Q2 2025 and expects to reach full enrollment in Q2 2026, with the potential to seek early approval after full enrollment.

Management Comments

• CEL-SCI believes that the confirmatory study has a high likelihood of success based on the large survival benefit that has already been observed in the target population from the completed Phase III study.
• CEL-SCI aims to begin the 212-patient confirmatory registration study in Q1/Q2 2025, with full enrollment expected in Q2 2026 with the potential to seek early approval after full enrollment.

Industry Context

The report highlights the growing immunotherapy market and CEL-SCI's potential to participate in this market with Multikine, particularly in a niche where existing immunotherapies may not be as effective.

Comparison to Industry Standards

• The document mentions Keytruda and Opdivo, checkpoint inhibitors that are leading drugs for head and neck cancer, but notes that Multikine targets a different patient population (low PD-L1 expression) than these drugs, which are more effective in patients with high PD-L1 expression.
• The document does not provide specific comparisons to other companies or projects in terms of financial performance or clinical trial results, but it positions Multikine as a potential first-line treatment before surgery, which differentiates it from currently available immunotherapies.

Stakeholder Impact

• Positive impact on patients with head and neck cancer if Multikine is approved.
• Potential positive impact on shareholders if the confirmatory study is successful and Multikine is commercialized.
• Continued employment for employees involved in the development and manufacturing of Multikine.

Next Steps

• Initiate the confirmatory registration study of Multikine in Q1/Q2 2025.
• Achieve full enrollment in the confirmatory study by Q2 2026.
• Seek potential early approval of Multikine after full enrollment.
• Raise additional capital to fund the confirmatory study and other research efforts.

Key Dates